BioLineRx Reports Publication of Positive Phase 1/2 Results in Stem Cell … – Benzinga
|
BioLineRx Reports Publication of Positive Phase 1/2 Results in Stem Cell …
Benzinga BioLineRx (NASDAQ: BLRX) announced today the publication of results showing that BL-8040 (formerly known as BKT-140) enables the efficient mobilization of stem cells from the bone marrow into the peripheral blood, thus facilitating autologous stem cell … |
